GNLX Stock Price
Genelux Corporation
GNLX stock price is $2.32 (-7.94% on the day), giving Genelux Corporation a market cap of $104.97M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
GNLX Stock Overview
- Price
- $2.32
- Previous close
- $2.52
- Open
- $2.48
- Market cap
- $104.97M
- P/E ratio
- -3.3
- 52-week range
- $2.29 - $8.54
- 1-year price target
- $18.83
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSC
- MarketXLS Rank
- 32
About Genelux Corporation
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GNLX | $2.32 | -7.9% | 410.33K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |